利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

56 条记录 (耗时 0.044 秒)

    Ischemic tissue cell therapy
    31.
    发明授权
    Ischemic tissue cell therapy 有权
    缺血组织细胞治疗

    公开(公告)号：US08784802B2

    公开(公告)日：2014-07-22

    申请号：US13063456

    申请日：2009-09-14

    申请人： Paul R. Sanberg ,  Nelson Americo Hossne, Jr. ,  Alison E. Willing ,  Adriana Invitti

    发明人： Paul R. Sanberg ,  Nelson Americo Hossne, Jr. ,  Alison E. Willing ,  Adriana Invitti

    IPC分类号： A61K35/14

    CPC分类号： A61K35/15 ,  A61K35/44 ,  A61K2035/124 ,  C12N5/0634 ,  C12N5/0645

    摘要： The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.

    摘要翻译： 本发明涉及用于治疗缺血性疾病和病症，特别是心肌，CNS /脑和肢体缺血的组合物和方法。 更具体地，本发明提供了通过从需要治疗的个体施用从血液（包括脐带血，外周血或骨髓）获得的单核细胞来治疗疾病的方法，其中在具体时间点向个体施用药物 确定提供治疗功效。 在一个实施方案中，细胞用于注射到缺血心肌中用于治疗心绞痛。

    METHODS OF TREATING STROKE USING STEM CELL-LIKE MENSTRUAL BLOOD CELLS
    32.
    发明申请
    METHODS OF TREATING STROKE USING STEM CELL-LIKE MENSTRUAL BLOOD CELLS 有权
    使用干细胞样淋巴细胞治疗小肠的方法

    公开(公告)号：US20110268710A1

    公开(公告)日：2011-11-03

    申请号：US13107391

    申请日：2011-05-13

    申请人： Paul R. Sanberg ,  Cesario V. Borlongan ,  Julie Allickson

    发明人： Paul R. Sanberg ,  Cesario V. Borlongan ,  Julie Allickson

    IPC分类号： A61K35/14 ,  A61P9/10 ,  A61K38/18

    CPC分类号： A61K35/14 ,  A61K35/30 ,  A61K38/185 ,  A61K38/1866

    摘要： A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death. Transplantation of menstrual blood-derived stem cells, either intracerebrally or intravenously, after experimentally induced ischemic stroke in adult rats also significantly reduced behavioral and histological impairments compared to vehicle-infused rats.

    摘要翻译： 与移植受体完全匹配的细胞类型似乎是最佳方案，以最小的并发症向大量患者群体开放治疗选择。 已经提出使用自体骨髓或脐带血作为细胞治疗的干细胞的良好来源。 月经血被认为是干细胞的另一个重要来源。 培养的月经血液的测定显示它们在合适的条件培养基下表达胚胎样干细胞表型标记物和神经元表型标记物。 氧葡萄糖剥夺中风模型显示，OGD暴露的原代大鼠神经元，与月经血源干细胞共培养或暴露于来自培养的月经血液的培养基，显示出显着降低的细胞死亡。 在实验性诱导的成年大鼠缺血性卒中后，月经血液或静脉内移植月经血源性干细胞也显着降低与载体输注大鼠相比的行为和组织学损伤。

    HUMAN IMMUNOSUPPRESSIVE PROTEIN
    33.
    发明申请
    HUMAN IMMUNOSUPPRESSIVE PROTEIN 有权
    人类免疫抑制蛋白

    公开(公告)号：US20080280812A1

    公开(公告)日：2008-11-13

    申请号：US12118675

    申请日：2008-05-09

    申请人： Paul R. Sanberg ,  Robert W. Engelman ,  William R. Gower

    发明人： Paul R. Sanberg ,  Robert W. Engelman ,  William R. Gower

    IPC分类号： A61K38/02 ,  A61P29/00

    CPC分类号： C07K14/4703 ,  A61K38/00 ,  Y02A50/471

    摘要： A method for purifying an immunosuppressant protein (HISP) has the steps of obtaining supernatant from hNT cells; exposing the supernatant to preparative polyacrylamide gel electrophoresis to produce 20 isoelectric fractions, including active isoelectric fraction #10; placing the active isoelectric fraction on a Blue Sepharose column to bind albumin; and collecting the free fraction containing the concentrated, isolated HISP. Also disclosed is a method of treating inflammation, using an effective amount of an HISP. The HISP is anionic, has a molecular weight of 40-100 kDa, an isoelectric point of about 4.8 and is obtained from the supernatant of hNT cells, but not from NCCIT embryonal carcinoma cells. T98G glioblastoma cells or THP-1 monocytic leukemia cells. HISP can maintain T cells in a quiescent G.sub.0/G.sub.1 state without lowering their viability. HISP loses activity when treated with heat, pH2, pH11, or mixed with trypsin or carboxypeptidase, but not with neuraminidase. HISP can suppress proliferation of responder peripheral blood mononuclear cells in allogeneic mixed lymphocyte cultures; HISP can suppress T-cell proliferation and IL-2 production in response to phorbol 12-myristate 13-acetate (PMA), ionomycin and concanavalin-A. HISP does not bind to heparin-sepharose CL-B gel; or to albumin-binding resin Blue Sepharose, HISP is concentrated with YM10 ultrafiltration. HISP does not act through the T-cell receptor-CD3 complex or via altered accessory signal cells. A method of treating inflammation comprises administering an effective amount of hNT neuronal cells.

    摘要翻译： 纯化免疫抑制蛋白（HISP）的方法具有从hNT细胞获得上清液的步骤; 将上清液暴露于制备型聚丙烯酰胺凝胶电泳以产生20个等电点，包括活性等电点＃10; 将活性等电点部分置于蓝色琼脂糖凝胶柱上以结合白蛋白; 并收集含有浓缩，分离的HISP的游离级分。 还公开了使用有效量的HISP治疗炎症的方法。 HISP是阴离子型的，分子量为40-100kDa，等电点约为4.8，从hNT细胞的上清中获得，但不是来自NCCIT胚胎癌细胞。 T98G胶质母细胞瘤细胞或THP-1单核细胞白血病细胞。 HISP可以将T细胞维持在静止的G.sub.0 / G.sub.1状态，而不降低其活力。 当用热，pH2，pH11处理或与胰蛋白酶或羧肽酶混合时，HISP失去活性，但不与神经氨酸酶混合。 HISP可以抑制同种异体混合淋巴细胞培养物中应答者外周血单核细胞的增殖; HISP可以抑制佛波醇12-肉豆蔻酸酯13-乙酸酯（PMA），离子霉素和伴刀豆素A的T细胞增殖和IL-2产生。 HISP不结合肝素 - 琼脂糖CL-B凝胶; 或白蛋白结合树脂蓝色琼脂糖，HISP用YM10超滤浓缩。 HISP不通过T细胞受体-CD3复合物或通过改变的附属信号细胞起作用。 治疗炎症的方法包括施用有效量的hNT神经元细胞。

    Implantable therapy systems and methods
    36.
    发明授权
    Implantable therapy systems and methods 失效
    植入式治疗系统和方法

    公开(公告)号：US06179826B2

    公开(公告)日：2001-01-30

    申请号：US08741228

    申请日：1996-10-29

    申请人： Patrick Aebischer ,  Moses Goddard ,  John G. Moldauer ,  Paul J. Mulhauser ,  Anne M. Rathbun ,  Paul R. Sanberg ,  Alfred V. Vasconcellos ,  Nicholas F. Warner

    发明人： Patrick Aebischer ,  Moses Goddard ,  John G. Moldauer ,  Paul J. Mulhauser ,  Anne M. Rathbun ,  Paul R. Sanberg ,  Alfred V. Vasconcellos ,  Nicholas F. Warner

    IPC分类号： A61M3100

    CPC分类号： A61K9/0092 ,  A61F2/022 ,  A61K9/0024 ,  A61K9/0085 ,  A61K35/55 ,  A61K2035/126 ,  A61M31/002 ,  A61M37/0069 ,  A61M39/0208 ,  A61M2210/0687 ,  A61M2210/0693 ,  B01J13/02 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  C12N5/0676 ,  C12N11/04 ,  C12N2533/30 ,  A61M2230/005

    摘要： Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a dibilatating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12). The obturator (30) is then removed from the cannula (20), and a biocompatible tethered vehicle (40) containing a biologically active material is inserted into the cannula along the passageway. A pusher can be inserted within the cannula, behind the vehicle (40), to position the proximal end of the vehicle at the proximal tip of the cannula (20b). Once the vehicle (40) is positioned near the proximal end of the cannula (20), the cannula is removed from the passageway, followed by the pusher, leaving the vehicle (40) positioned at the treatment site (12).

    摘要翻译： 公开了植入式治疗系统，用于将局部和受控制的生物活性因子递送至患有二体化病症的受试者的脑，脊髓和其他靶区域。 本发明的方法涉及通常在患者体内暴露通常位于预定治疗部位（12）上方的插入部位。 具有定位在其中的闭塞器（30）或扩张器（104）的插管（20）插入插入位置，从而限定到治疗部位的通路。 在一些情况下，套管可以沿着预先位于治疗部位的导丝（102）的路径插入。 插管（20）优选为低摩擦聚合材料，例如聚四氟乙烯。 插管（20）通常具有用于接收封闭器（30）或扩张器（104）的开放近端，以及用于将神经活性因子递送至治疗部位（12）的开口远端，优选地为锥形末端。 然后将塞子（30）从插管（20）中取出，并且将包含生物活性物质的生物相容性系留载体（40）沿通道插入插管中。 推动器可以插入插管内，在车辆（40）后面，以将车辆的近端定位在套管（20b）的近端处。 一旦车辆（40）定位在套管（20）的近端附近，则套管从通道中移开，随后是推动器，使车辆（40）位于治疗部位（12）处。